检索

期
标题
作者
卷 30, 编号 14 (2023)
The role of cyclin-dependent kinase inhibitors in adjuvant therapy of breast cancer
Semiglazov V., Krivorotko P., Bekkeldiyeva N., Komyakhov A., Emelyanov A., Gorina A.
PDF
(Rus)
卷 28, 编号 11 (2021)
Ways to improve endocrine therapy in postmenopausal women with ER+/ HER2- breast cancer
Dzhelyalova M., Semiglazov V.
PDF
(Rus)
编号 17 (2016)
FIRST-LINE ENDOCRINE THERAPY OF HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER. TIME OF CHANGE AFTER A LONG-TERM CALM PERIOD
Zhukova L., Manikhas A.
PDF
(Rus)
卷 28, 编号 7 (2021)
Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
Grechukhina K., Vorontsova K., Kuko T., Prosvirnov A., Ganshina I., Lubennikova E., Kolyadina I., Zhukova L.
PDF
(Rus)
编号 17 (2014)
Osobennosti klinicheskogo techeniya invazivnogo dol'kovogo raka molochnoy zhelezy
Borisova E., Vyshinskaya G., Gutorov S., Stepanchenko M.
PDF
(Rus)
卷 27, 编号 11 (2020)
Endocrine resistance in breast cancer treatment
Dzhelyalova M., Semiglazov V.
PDF
(Rus)
编号 18 (2012)
Hormonal treatment of breast cancer: optimal sequence and issues of overcoming the resistance
Borisova E., Gutorov S., Vorontsov A.
PDF
(Rus)
卷 27, 编号 7 (2020)
Abemacyclib - new options for the treatment of hormone-positive metastatic breast cancer with CDK4/6 inhibitors
Semiglazova T., Volynshchikova O., Semiglazov V., Klimenko V., Brish N., Alekseeva Y., Klyuge V., Krutov A., Paltuev R., Kasparov B., Krivorotko P., Semiglazov V.
PDF
(Rus)
编号 18 (2009)
RAK MOLOChNOY ZhELEZY I BEREMENNOST'
Dashyan G., Semiglazov V., Semiglazov V., Migmanova N., Krivorot'ko P., Tabagua T., Vasil'ev A.
卷 27, 编号 7 (2020)
Alpelisib for the treatment of HR+HER2-metastatic breast cancer in patients with the PIK3CA mutation: results of the SOLAR-1 study
Semiglazova T., Semiglazov V., Klimenko V., Brish N., Alekseeva Y., Klyuge V., Krutov A., Paltuev R., Kasparov B., Krivorotko P., Semiglazov V.
PDF
(Rus)
编号 1S (2009)
NEOAD\"YuVANTNAYa ENDOKRINOTERAPIYa RAKA MOLOChNOY ZhELEZY
Semiglazov V., Semiglazov V., Ivanov V.
卷 26, 编号 7 (2019)
Prognostic and predictive values of the PIK3CA gene mutation in patients with breast cancer
Semiglazova T., Sorokina I.
PDF
(Rus)
编号 7 (2018)
CYCLIN-DEPENDENT KINASE INHIBITORS - NEW THERAPEUTIC OPTION FOR PATIENTS WITH HORMONE-DEPENDENT HER2-NEGATIVE BREAST CANCER: CLINICAL EXPERIENCE
Sakaev D., Iskhakova A., Kunafina R.
PDF
(Rus)
编号 17 (2017)
Palbociclib - new possibilities of therapy of hormon-positive HER2-negative breast cancer
Zhukova L., Chichikov E., Gordeeva O., Filonenko D.
PDF
(Rus)
1 - 14 的 14 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回（例如，隐含AND）
  • 使用OR结合多个检索词，便于查找含有这些检索词的文章，例如education OR research
  • 使用括号来创建更复杂的查询; 例如：archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如： "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如：online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语
##common.cookie##